A retrospective observational to determine risk of risk of stroke/systemic embolism and major bleeding among non-valvular atrial fibrillation patients with prior bleeding events treated with NOACs
Latest Information Update: 30 Nov 2021
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Embolism; Thromboembolism
- Focus Therapeutic Use
- 30 Nov 2021 New trial record